Federal Rule Cuts Minor Trans Care Funding

The Trump administration finalized a rule barring federal Medicaid and CHIP funding for puberty blockers, cross-sex hormones, and gender-affirming surgeries for youths (under 18 for Medicaid, under 19 for some CHIP programs), with the policy taking effect in October 2026 and a six-month tapering option for those already on hormone therapy. States may continue funding these treatments with state funds or private insurance, and exemptions remain for certain conditions such as disorders of sexual development or care problems arising from prior procedures; mental-health services will continue to be funded. The policy is part of a broader move restricting transgender healthcare for minors, arguing interventions have weak evidence of benefit and carry irreversible risks, while major medical groups urge decisions to rest with families and clinicians. Reactions are mixed, with supporters saying the change protects children and saves taxpayer dollars and opponents warning of legal challenges and reduced access for low-income families; some states, like Massachusetts, indicate they will cover care with state funds. The rollout occurs amid ongoing national debates over transgender rights, medical consensus, and the balance between science and policy.